|
The LentiVector system enables safe, stable and efficient delivery of genetic sequences into multiple cell types. It is widely used in drug discovery and target validation. In addition, its unique characteristics make it an ideal vector system for gene and RNAi-based therapies in many therapeutic areas.
|
 |
The 5T4 tumour antigen is a unique protein found on most common types of solid cancer, which makes it a potentially valuable target for novel anti-cancer interventions.
|
|
The Hi-8 PrimeBoost technology is based on the use of heterologous vectors to stimulate specific cellular immune responses against diseased cells, even those expressing very low levels of the target antigen.
|
|
Gene-Directed Enzyme Prodrug Therapy (GDEPT) is a therapeutic strategy to enhance the safety and effectiveness of prodrugs. Through targeted delivery of an enzyme to diseased cells, the technology enables prodrug activation at the site of disease.
|
|
The anti-angiogenesis technology is an anti-cancer therapeutic strategy to deliver the genes for two potent anti-angiogenic agents, endostatin and angiostatin, using viral vectors.
|
|
|
